L3VLUP
ProSign in

DHR · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DHRLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DHR
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterDHRLLY
Q3 202032 holders, $29.1bn33 holders, $14.1bn
Q4 202036 holders, $29.1bn29 holders, $17.3bn
Q1 202139 holders, $29.4bn24 holders, $23.0bn
Q2 202130 holders, $33.9bn24 holders, $27.8bn
Q3 202135 holders, $37.5bn31 holders, $29.9bn
Q4 202140 holders, $39.7bn31 holders, $34.7bn
Q1 202230 holders, $33.5bn24 holders, $35.3bn
Q2 202230 holders, $28.1bn33 holders, $42.7bn
Q3 202229 holders, $27.1bn31 holders, $43.4bn
Q4 202231 holders, $27.1bn31 holders, $46.6bn
Q1 202340 holders, $25.3bn33 holders, $44.3bn
Q2 202344 holders, $25.4bn37 holders, $59.6bn
Q3 202338 holders, $27.3bn44 holders, $67.6bn
Q4 202332 holders, $25.2bn45 holders, $73.6bn
Q1 202433 holders, $26.8bn41 holders, $95.3bn
Q2 202425 holders, $25.0bn43 holders, $110bn
Q3 202430 holders, $29.0bn45 holders, $107bn
Q4 202433 holders, $23.9bn46 holders, $93.9bn
Q1 202543 holders, $21.5bn42 holders, $98.4bn
Q2 202541 holders, $18.6bn43 holders, $93.2bn
Q3 202538 holders, $15.9bn39 holders, $86.7bn
Q4 202539 holders, $20.4bn41 holders, $123bn
Q1 202636 holders, $19.5bn39 holders, $106bn
Q2 202637 holders, $20.8bn44 holders, $132bn
DHR

Danaher Corp Del

Holders
38
Reported value
$15.9bn
Buyers
21
Sellers
21

Breadth 0 among 95 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DHR (11)

Akre Capital Management LLC, D1 Capital Partners LP, Glenview Capital Management LLC, Maverick Capital Ltd, MFS Investment Management, Point72 Asset Management LP, Rokos Capital Management LLP, Soroban Capital Partners LP, Third Point LLC, Tudor Investment Corp, Viking Global Investors LP

Only LLY (12)

Acadian Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Marshall Wace LLP, Polen Capital Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →